The companion animal drugs market is estimated to reach USD 16,131.2 million in 2024. It is estimated that revenue will increase at a CAGR of 6.2% between 2024 and 2034. The industry is anticipated to reach USD 29,329.2 million by 2034.
The companion animal drugs market is experiencing a transformative phase within precision medicine, driven by innovations that ensure the efficacy and personalization of therapies. By integrating cutting-edge technologies such as next-generation sequencing (NGS), proteomics, and AI-led analytics, manufacturers are able to identify specific biomarkers that directly influence the design and performance of therapeutic solutions.
These advancements not only optimize drug efficacy but also improve safety profiles by tailoring treatments to individual animals' biological characteristics.
The growing role of data analytics and artificial intelligence in companion drug development allows companies to predict treatment outcomes more accurately. This integration helps monitor the progression of conditions in real-time, ensuring that therapies remain effective throughout their application. By incorporating such tools, manufacturers enhance their ability to develop therapies that are highly specific, providing pets with individualized care options.
Companion Animal Drugs Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 15,197.6 million |
| Estimated Size, 2024 | USD 16,131.2 million |
| Projected Size, 2034 | USD 29,329.2 million |
| Value-based CAGR (2024 to 2034) | 6.2% |
More players venture into manufacturing expansions, which is a major driving force in growing the companion animal drugs market. In keeping with the higher demand for animal health solutions, market leaders elevate their strategy in investing in expansion and betterment of their production capabilities. All of such endeavors display the proactive approach of the industry toward reckoning with the changing requirements of veterinary and pet care practice.
For example, in January 2023, MSD Animal Health, a pharmaceutical company, opened a state-of-the-art facility for the production of animal vaccines in the Brabant region of the Netherlands. This facility is situated in Boxmeer and is, thus far, the largest one in the world dedicated to the development and manufacture of animal vaccines and holds the potential of producing 55 billion doses each year.
The trend of expanding manufacturing facilities amply demonstrates the commitment of market leaders to meeting the increasing demand for companion animal drugs. Besides expanded production capabilities, manufacturers are also investing in advanced manufacturing technology to ensure the quality and efficiency of companion animal drugs production.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Comparative analysis of fluctuations in compound annual growth rate (CAGR) for the global companion animal drugs market between 2023 and 2024 on six months basis is shown below. By this examination, major variations in the performance of these markets are brought to light, and also trends of revenue generation are captured hence offering stakeholders useful ideas on how to carry on with the market’s growth path in any other given year. January through June covers the first part of the year called half1 (H1), while half2 (H2) represents July to December.
The below table presents the expected CAGR for the global companion animal drugs market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 6.9% followed by a slight decline in the growth rate which will grow at 4.8% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 6.9% (2023 to 2033) |
| H2 | 6.6% (2023 to 2033) |
| H1 | 6.2% (2024 to 2034) |
| H2 | 5.7% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 6.2% in the first half and remain relatively moderate at 5.7% in the second half. In the first half (H1) the market witnessed a decrease of 70 BPS similar with the second half (H2), the market witnessed a decrease of 90 BPS.
Increasing Pet Insurance Adoption Boosts the Need for Companion Drugs
Growing pet insurance adoption is one of the most influential drivers for the companion animal drugs market, fostering the growth of advanced precision healthcare solutions. According to NAPHIA's State of the Industry Report 2024, pet insurance premium volume reached USD 3.9 million in the USA in 2023, with insured pets increasing to nearly 5.7 million, thus an increase of 17% compared to 2022. Dogs accounted for 80% of insured pets, with accident and illness while cats made up 20%.
The increasing availability and adoption of pet insurance ensure that owners can afford advanced therapeutics, thus driving demand for innovative drugs addressing chronic and severe conditions. With insurance covering significant treatment costs, companion drugs designed to manage and treat these conditions become more accessible, encouraging the development of targeted therapies.
Overall, increasing adoption of pet insurance allows for broader access to the most advanced treatments and thus influences the development of more precise and effective companion drugs. This indicates that affordability, combined with advances in veterinary medicine, is changing the companion animal drugs market and driving innovation to raise the quality of pet healthcare globally.
Collaboration between Small Market Players to Strengthen Product Portfolio
Collaborations between key industry players are becoming a powerful trend in the companion animal drugs market, helping smaller companies expand their global reach and boost their market position. By partnering with larger or complementary firms, these companies can access shared expertise, research capabilities, and resources to accelerate the development of innovative products that address emerging health needs in pets.
For example, in November 2023, Adopt a Pet and Zoetis, two prominent USA pet industry leaders, partnered to enhance access to care for shelter pets. This initiative not only focuses on providing better veterinary services but also includes educational resources for veterinary healthcare teams in shelters and pet owners nationwide.
This type of collaboration demonstrates how shared goals and pooled resources can create a broader impact on the market, driving advancements in animal healthcare and opening doors for specialized companion animal drugs.
The increased access to joint expertise and shared resources supports the development of innovative companion animal drugs that cater to evolving consumer needs and address emerging health concerns. This trend of collaboration enables smaller companies to leverage the strengths of their partners, foster innovation, and build competitive advantage.
By tapping into new markets and aligning with established names, smaller players can ensure long-term growth and contribute to the overall success and expansion of the global companion animal drugs market.
Manufacturers Partner with Organizations to Raise Awareness of Pet Health Challenges
Raising awareness about chronic pain in pets is on the rise, on the back of creating trends in the companion animal drugs market. On September 20, 2024, Zoetis and the Arthritis Foundation announced a two-year partnership to educate owners of cats and dogs about osteoarthritis (OA) pain.
This collaborative effort intends to bring attention to the awareness of OA pain because this condition mainly goes unnoticed among pets despite its increasing recognition. The inaugural step is directed toward understanding the rising demand for treatment solutions for this often underdiagnosed condition.
Such collaborations give an increasing emphasis on the improvement of pets' quality of life by precision drug developments. Emerging discoveries in this segment concentrate on the development of early OA main biomarkers enabling timely incidence and effective management. In addition, awareness about chronic pain conditions suffered by pets is rising, fueling the demand for sophisticated treatment solutions beyond traditional veterinary measures.
A parallel transition of veterinary health toward personalized solutions is the embodiment of this trend being opportune for the companion animal drugs market for extending further influence and impact in animal health.
Lack of Awareness of Animal Vaccines Hampers Companion Animal Drugs Market Growth
A significant restraining factor for the companion animal drugs market is the large gap in understanding the epidemiological patterns of veterinary diseases, which vary greatly in endemic countries. A prime example of this is newcastle disease in poultry; the lack of comprehensive epidemiological knowledge about this disease results in severe economic losses in international poultry trade.
In many developing countries, people lack awareness regarding certain serious companion animal diseases as opposed to livestock diseases, which are more regularly monitored. This is primarily true with regard to pet vaccinations, which is a mandatory requirement for up to three years. Additionally, parasitic medications for companion animals and livestock are different. Lack of awareness with regard to the differentiation of these medication varieties leads to adverse drug side effects and thus low administration of companion animal medications.
Marketplace discussions indicate that veterinary research institutes must maintain closer collaborations with vaccine manufacturers to gain deeper insights into antigen/immunogenic structures, vaccine mechanisms, and correlates of symptoms treatable by these vaccines. This collaboration is crucial for addressing knowledge gaps and improving vaccine development processes.
Overall, these challenges highlight the critical need for enhanced epidemiological research and closer industry collaboration to overcome barriers in vaccine development and protect animal health effectively.
Principal Consultant
The companion animal drugs industry recorded a CAGR of 5.0% between 2019 and 2023. According to the industry, companion animal drugs generated USD 15,197.6 million in 2023, up from USD 12,460.8 million in 2019.
Between 2019 and 2023, the companion animal drug market demonstrated steady growth, driven by advancements in targeted therapies and increased adoption of precision medicine. In these years, manufacturers started to turn their attention to producing more specialized drugs directed at specific pet health conditions. Intensive work in research laboratories to develop biomarkers and their applications in companion drugs progressed rapidly, especially for chronic ailments such as arthritis and heart problems.
Trends in pet ownership greatly influenced the market dynamics. Higher rates of pet adoptions, particularly in developed nations, drove the need for improved healthcare options. Preventative health care further led to drug developments that could not only treat but also prevent common pet ailments. The availability of affordable pet insurance also benefitted this trend, permitting pet owners to opt for advanced therapies.
It is expected that the companion animal drugs market will be shaped by innovations in personalized therapies and increased collaborations between manufacturers and veterinary healthcare providers. The advances in genomics and biotechnology will allow therapies to come into existence that are very specific and targeted, especially concerning behavioral and chronic conditions. Personalized treatments for skin disorders might become more common, for example, as companies leverage data to tailor solutions to pets.
Sustainability is increasingly emerging as a focal area. Some manufacturers are responding to a growing consumer call for a sustainable approach through investments in eco-friendly drug design and packaging. Besides, it is expected that digital health tools, such as health trackers with wearables for pets, will be able to integrate with companion drugs, providing real-time monitoring of treatment success and improving proactive health management.
The role of regulatory frameworks will similarly expand, supportive governments and institutions helping innovation in veterinary pharmaceuticals. Emerging economies will also grow comparatively faster since the growing disposable incomes enable owners to pay for veterinary health care and provide time for awareness of pet health. These trends collectively indicate a dynamic shift towards a more advanced and accessible future for the companion animal drugs market.
Tier 1 includes companies cumulatively holding around 44.4% share of the total market revenue. Tier 1 players dominate the market due to their extensive and diverse product portfolios that cover a wide range of therapeutic areas, such as antibiotics, vaccines, parasiticides, and skin care products.
Tier 1 players operate on a global scale, with strong distribution networks and partnerships that enable their products to reach diverse markets, including emerging economies. The companies that comprise tier I are Zoetis Inc., Merck & Co, Ltd., Bayer AG, and Elanco.
Tier 2 includes companies cumulatively holding around 14.8% share of the total market revenue. The companies that comprise tier II are Boehringer Ingelheim GmbH (Merial), Virbac Animal Health, Ceva Santè Animale, and others. These companies' players often focus on providing cost-effective alternatives to Tier 1 products, catering to price-sensitive parents.
Unlike Tier 1 players, Tier 2 companies usually have a strong regional focus. They excel in catering to local markets, understanding regional regulatory frameworks, and addressing specific health issues prevalent in those areas.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
An analysis of the companion animal drugs industry is provided in various countries. Several regions throughout the world are examined, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East & Africa. India is forecast to remain the leader of South Asia & Pacific with a 8.1% CAGR through 2034. The United States is predicted to exhibit a 6.9% CAGR by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 6.9% |
| Germany | 6.5% |
| France | 7.9% |
| China | 8.4% |
| India | 8.1% |
The United States is leading the companion animal drugs market around the globe with CAGR of 6.9%. The serious health aspect of osteoarthritis (OA) as a problem of amply wide recognizance and concern among owners of pets in the United States.
It is estimated that about 14 million adult dogs are affected by osteoarthritis, making it one of the highest health problems encountered by pets. Such an alarming prevalence of osteoarthritis in aged animals has requested medicine and treatment as efficient means of controlling pain and improving mobility, which raises the question of what companion drugs could serve in OA management in the market.
Osteoarthritis remains a leading problem for pets, and this, in turn, has forced veterinary pharmaceutical establishments in the United States to devote the next few years to developing targeted drugs for treating it: pain relievers, anti-inflammatory drugs, and joint supplements that work toward alleviating the symptoms of OA and improving the quality of life for afflicted pets, indeed bringing to the surface a niche in the market for these companion drugs for OA management.
Germany is leading the companion animal drugs market in Western Europe with CAGR of 6.5%. Germany is well established when it comes to veterinary healthcare. Medical advances have resulted in growing demand for specialist treatment of pets-from chronic conditions like arthritis to acute infections, and ultimately high-quality medicament for companion pets has never appeared as critical.
Germany is investing in veterinary science; its focus is on innovation concerning new developments in medicine, aimed at companion animals. Companies embark on producing innovative drugs for the management of chronic ailments, developing increasingly sophisticated diagnostic techniques, and providing treatment tailored to specific patients. This is enhanced by the integration of cutting-edge technology in veterinary practice, making sure every pet gets the best possible care.
Germany’s commitment to advancing veterinary healthcare and the demand for specialized treatments are key drivers of growth in the companion animal drugs market, making it one of the most developed markets in Europe.
China is leading the companion animal drugs market in East Asia with CAGR of 8.4%. In China, pet ownership has been growing rapidly, particularly in urban areas. According to the Pet Industry White Paper issued by Pethadoop in 2023, there are over 120 million pets in the country. While the number of dogs decreased by 9% compared to 2022, they still accounted for 44% of all pets. On the other hand, the number of cats increased by 6% annually, making up 70% of the total pet population.
As more pet owners are paying attention to the advancement of pet healthcare, which means they require vaccines, anti-inflammatory drugs, and parasite control medications. With the increasing ownership of pets and urbanization, China's companion animal drugs market is expanding, aided by a huge demand for better pet healthcare medicines. This trend is expected to linger as the middle classes in urban centers expand and preferential treatment towards pet health and wellbeing grows.
A description of the leading segments in the industry is provided in this section. Parasiticides are estimated to hold 28.7% of the value share in 2024 by product category whereas, institutional sales will be the leading end user with a high share of 57.8% in the market in 2024.
| Product | Parasiticides |
|---|---|
| Value Share (2024) | 28.7% |
In the companion animal drugs market, parasiticides will lead the market in 2024 with 28.7%. To meet the growing need for preventive measures for animal diseases, animal health companies are coming into advanced drug developments. Parasiticides are quite crucial in the elimination of harmful parasites, such as fleas, worms, and insects, which infect several animals-including household pets like dogs, and companion species.
In small animal medicine, these are key therapeutics for treating and managing parasitic diseases. Beyond promoting the welfare and health of animals, there are also zoonotic soil-borne diseases, protecting public health and safety, which are prevented.
With rising demand for parasiticides in the market, it underscores the role they play in maintaining overall health among companion animals in preventing diseases caused by parasites.
| Distribution Channel | Institutional Sales |
|---|---|
| Value Share (2024) | 57.8% |
Institutional sales will dominate the companion animal drugs market with the highest share of 57.8% in 2024. Institutional sales such as veterinary hospitals typically include more services than possible through different distribution channels such as pharmacies or drug stores. They managed to provide special treatment, may have facilities to provide surgical techniques, and are also equipped for emergency care, which makes them an obvious choice for pet owners seeking a more broad-spectrum approach to health.
This ensures a continuous demand for several companion drugs such as parasiticides, antibiotics, pain management drugs, and so forth. Most pet owners visit veterinary hospitals for diagnosis and treatment of their pets' health problems.
They also prefer to have continuous care; thus, veterinary hospitals become the place where most medications are accessed by pet parents. This creates a source of continuous customer flow, and thus, demand for companion drugs is created, contributing immensely to the market share that veterinary hospitals hold.
The companion animal drugs market is highly fragmented, with a large number of global, regional, and niche players actively competing across various therapeutic categories. This diverse and competitive landscape is primarily driven by continuous product development and regulatory approvals, as companies strive to meet the evolving demands of pet owners. Key players in the market are heavily focused on advancing their product portfolios to cater to a wide range of health concerns, such as parasitic infections, pain management, and preventive care.
Recent Industry Developments in the Companion Animal Drugs Market:
In terms of product type, the industry is segregated into anti-infective agents (antibiotics & antimicrobials, anti-fungal, anti-viral), anti-inflammatory & analgesic agents (non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioids, other), parasiticides (endo-parasiticides, ecto-parasiticides, endectocides), vaccines, hormones & substitutes, nutritional products, other products.
In terms of animal type, the industry is segregated into cats, dogs, horse, rabbits, birds and other animals
In terms of route of administration, the industry is segregated into oral route (tablets/capsules, liquids, powders/premix, other oral route), parenteral route (liquids, powder for injection), topical route, (solutions, creams & ointments), others
In terms of disease indication, the industry is segregated into allergy, infectious disease, diabetes, oncology, osteoarthritis, metabolic diseases, cardiac diseases, reproductive disorders, and other indications
In terms of distribution channel, the industry is segregated into institutional sales (veterinary hospitals, veterinary clinics), retail sales (retail pharmacies, drug stores, online pharmacies, hypermarket and supermarkets, and pet shops)
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East & Africa have been covered in the report.
The companion animal drugs market is expected to increase at a CAGR of 6.2% between 2024 and 2034.
Parasiticides segment is expected to occupy a 28.7% market share in 2024.
The market for companion animal drugs is expected to reach USD 29,329.2 million by 2034.
The United States is forecast to see a CAGR of 6.9% during the assessment period.
The key players in the companion animal drugs industry include Zoetis, Inc., Merck Animal Health, Boehringer Ingelheim GmbH, Elanco (Eli Lilly and Company), Zydus Life Sciences (Zenex Animal Health Pvt. Ltd.), Ceva Santé Companion Animal, Virbac SA, Vetoquinol S.A., Hester Biosciences Limited, Dechra Pharmaceuticals PLC, Ayurvet, Vetpharma, Shennong Animal Health, Intas Pharmaceuticals Ltd., and Alivira Animal Health Limited
Explore Healthcare Insights
View Reports
Companion Animal Drugs Market
